Search

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

… Tuesday, December 5, 2017 This past year, Memorial Sloan Kettering researchers made important advances in basic and translational science that furthered our understanding of cancer and of how best to treat it. Here, we describe some of the year’s highlights. First CAR T Cell Therapies FDA Approved By

Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.

… Wednesday, April 30, 2025 MSK recently announced the launch of a new cohort program in the MSK Therapeutics Accelerator . Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK’s drug development resources and a pathway

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.

… Friday, February 5, 2021 Summary Research shows how a protein called MYB can be targeted, suggesting a new approach for drugs that could treat a range of cancers, especially myeloid leukemias in both children and adults. Disruption in the way genes turn on and off can cause tumors to grow and proliferate

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different mutational processes impact individual cell genomes in cancer; sheds new light on cell senescence in cancer; and offers new models to aid the search for new treatments for mesothelioma.

… Wednesday, November 23, 2022 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different

The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

… Thursday, December 6, 2012 Summary The initiative, focused on investigators from Memorial Sloan Kettering’s Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research. The Geoffrey Beene Foundation is featuring six Memorial Sloan Kettering researchers in its current

Discover how Memorial Sloan Kettering is teaming up with local hospitals to promote healthy eating in diverse communities.

… Monday, October 4, 2021 Update: On June 16, 2022 Dr. Gany and her team published the results of a groundbreaking study, the first of its kind, in the  Journal of Clinical Oncology .  After six months of study enrollment, researchers found that patients who received a debit card for groceries and had

Descubre cómo Memorial Sloan Kettering se está uniendo a hospitales locales para promover la alimentación saludable en la comunidad latina.

… Monday, October 4, 2021 Se sabe que una dieta saludable ayuda a prevenir el cáncer. Pero una dieta saludable también es fundamental después de diagnosticar a los pacientes. Los tratamientos contra el cáncer pueden quitar el apetito a los pacientes. Sin embargo, deben alimentarse bien para estar lo suficientemente

The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge oncology research. ASCO 2021 will focus on Equity: Every Patient. Every Day. Everywhere.

… Wednesday, June 2, 2021 Thousands of oncology experts from around the world will tune in from June 4 to June 8 for the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting . The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and

Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.

… Sunday, June 5, 2022 Some members of the MSK team behind the groundbreaking research at the American Society of Clinical Oncology, June 2022 (l to r): Dr. Luis Diaz, Dr. Andrea Cercek, Jenna Sinopoli, clinical trials nurse, Jill Weiss, clinical research supervisor, Melissa Lumish, clinical fellow. Some

Researchers have found that the genetic changes that cause pediatric leukemia are different from those that lead to leukemia in adults.

… Monday, February 18, 2019 Summary The finding that the mutations behind certain pediatric blood cancers are different from those that trigger leukemia in adults helps explain why some leukemias in children are so difficult to treat. A study exploring the genetic landscape of leukemia in children has